# Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study

Study · id `cardio:ct-nct03037931` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03037931](<https://clinicaltrials.gov/study/NCT03037931>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03037931

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3065 participants.

## Technical summary

Registry record NCT03037931. Randomized; double masking; primary purpose treatment. Start 2017-03-15 (actual); primary completion 2023-02-02 (actual). Results posted on 2024-07-03.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3065 participants (enrolled count; ClinicalTrials.gov record NCT03037931, source copy `cardio:ctgov-nct03037931-2024-07-03`, retrieved 2026-10-26)
- Started: 2017-03-15 (actual) (ClinicalTrials.gov record NCT03037931, source copy `cardio:ctgov-nct03037931-2024-07-03`, retrieved 2026-10-26)
- Primary completion: 2023-02-02 (actual) (ClinicalTrials.gov record NCT03037931, source copy `cardio:ctgov-nct03037931-2024-07-03`, retrieved 2026-10-26)
- Completion: 2023-02-02 (actual) (ClinicalTrials.gov record NCT03037931, source copy `cardio:ctgov-nct03037931-2024-07-03`, retrieved 2026-10-26)
- Results first posted: 2024-07-03 (ClinicalTrials.gov record NCT03037931, source copy `cardio:ctgov-nct03037931-2024-07-03`, retrieved 2026-10-26)
- Countries: United States; Australia; Bulgaria; Canada; Czechia; Georgia; Hungary; Latvia; Lithuania; New Zealand; Poland; Russia; Ukraine (ClinicalTrials.gov record NCT03037931, source copy `cardio:ctgov-nct03037931-2024-07-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03037931-2024-07-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
- Acronym: HEART-FID
- Condition: Heart Failure
- Condition: Iron-deficiency
- Intervention (Drug): Ferric Carboxymaltose
- Intervention (Drug): Placebo
- Lead sponsor: American Regent, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Duke Clinical Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Ferric carboxymaltose (`core:ferric-carboxymaltose`)
- Registry lists this organization as a collaborator: Duke Clinical Research Institute (`cardio:org-duke-clinical-research-institute`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Ferric Carboxymaltose in Heart Failure with Iron Deficiency (`cardio:pubmed-37632463`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Functional and Prognostic Implications of Different Iron Deficiency Definitions in Heart Failure: Insights From HEART-FID (`cardio:pubmed-41137844`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e92a9ca90af31f0550c2032d38f0d2424ce7b8b7411b775330a31feec4d379ef
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
